Autolus Therapeutics AUTL 深 滬
已收盤 08-01 16:00:00 美东时间
2.35
-0.050
-2.08%
華盛通- 最 高2.36
- 今 開2.34
- 成交量 135.45万股
- 最 低 2.23
- 昨 收 2.40
- 總市值 6.25亿
- 52周最高 5.00
- 市盈率 靜 --
- 換手率 0.51%
- 52周最低 1.105
- 委 比 -43.11%
- 總股本 2.66亿
- 歷史最高 53.24
- 量 比 0.69
- 振 幅 5.42%
- 歷史最低 1.105
- 每 手 1
- 風險率 1.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
Autolus Therapeutics (Nasdaq: AUTL) will release its Q2 2025 financial results and operational highlights on August 12, 2025. A conference call at 8:30am EDT will discuss the results, with registration via the provided link. A webcast and replay will also be available on their website. The company focuses on developing next-generation T cell therapies for cancer and autoimmune diseases, with a marketed therapy, AUCATZYL®, and a pipeline of produc...
07-24 11:30
Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.
07-21 21:59
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
The European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The approval is based on the FELIX clinical trial, which showed a 76.6% complete response rate, a median response duration of 21.2 months, and low toxicity. The therapy involves CD19-targeted CAR T cells with a fast off-rate design. AUCATZYL is al...
07-21 11:00
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics授予60名员工总计360,550股股票期权，行使价为$2.47，期权有效期为10年，分四年归属，第一年归属25%，剩余部分每月归属，需员工持续服务。公司简介：Autolus是一家早期商业化阶段的生物制药公司，利用T细胞编程技术开发下一代T细胞疗法，用于治疗癌症和自身免疫疾病，已有已上市疗法AUCATZYL，并有多款候选产品在研。
07-15 20:05
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.
06-30 20:36
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- Equity Insider News Commentary – Rising rates of cancer are going to c...
06-25 00:52
BioNTech年底前关闭细胞疗法工厂、裁员
（转自：医趋势） 近日，BioNTech宣布逐步关闭其在美国的首个细胞疗法生产工厂。这一决策是由于该公司的一款CAR-T候选疗法在早期癌症试验中的表现未能达到...
06-20 11:40
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
Autolus Therapeutics presents updated FELIX study data on obe-cel for adult r/r B-ALL, showing a median response duration of 42.6 months, with over half of patients in remission at 24 months. Notably, 38% of ongoing responders did not require subsequent therapy by month 33. Results suggest obe-cel may offer durable remission without further treatment for some patients.
06-12 06:00
